Ser465

Site Information
PIsGHrAsPNPVAME SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 4751207

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 6 , 7 , 8 , 9 , 10 , 11 , 12 )
Disease tissue studied:	breast cancer ( 3 , 7 ) , breast ductal carcinoma ( 3 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 , 3 ) , cervical cancer ( 10 ) , cervical adenocarcinoma ( 10 ) , leukemia ( 8 , 12 ) , acute myelogenous leukemia ( 8 ) , chronic myelogenous leukemia ( 12 ) , lung cancer ( 7 ) , non-small cell lung cancer ( 7 ) , ovarian cancer ( 3 ) , melanoma skin cancer ( 2 )
Relevant cell line - cell type - tissue:	breast ( 1 , 3 ) , BT-20 (breast cell) ( 7 ) , Calu 6 (pulmonary) ( 7 ) , H2009 (pulmonary) ( 7 ) , H2077 (pulmonary) ( 7 ) , H2887 (pulmonary) ( 7 ) , H322M (pulmonary) ( 7 ) , HCC1937 (breast cell) ( 7 ) , HCC366 (pulmonary) ( 7 ) , HCC78 (pulmonary) ( 7 ) , HeLa (cervical) ( 6 , 9 ) , HeLa S3 (cervical) ( 10 , 11 ) , Jurkat (T lymphocyte) ( 4 ) , K562 (erythroid) ( 6 , 12 ) , KG-1 (myeloid) ( 8 ) , LOU-NH91 (squamous) ( 7 ) , MCF-7 (breast cell) ( 7 ) , MDA-MB-468 (breast cell) ( 7 ) , NCI-H1395 (pulmonary) ( 7 ) , NCI-H1648 (pulmonary) ( 7 ) , NCI-H2030 (pulmonary) ( 7 ) , NCI-H460 (pulmonary) ( 7 ) , NCI-H520 (squamous) ( 7 ) , ovary ( 3 ) , PC9 (pulmonary) ( 7 ) , WM239A (melanocyte) ( 2 )

Upstream Regulation
Treatments:	ischemia ( 3 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
3	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
4	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
5	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
6	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
7	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
8	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
9	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
10	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
11	Malik R, et al. (2009) Quantitative analysis of the human spindle phosphoproteome at distinct mitotic stages. J Proteome Res 8, 4553-63 19691289 Curated Info
12	Stokes M (2008) CST Curation Set: 4391; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info